An Open-Label Long-Term Phase 3 Study of CAM2029 in Patients with Acromegaly (ACROINNOVA 2): Interim Analysis of the Subgroup of Patients 'new to CAM2029' with Controlled or Uncontrolled Acromegaly on Standard-of-care Treatment